Search

Your search keyword '"Richard, Sandrine"' showing total 41 results
Start Over Author "Richard, Sandrine" Publication Year Range Last 10 years
41 results on '"Richard, Sandrine"'

3. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

BABA-HAMED, Nabil, BABIN, Emmanuel, BERA, Guillaume, BETRIAN-LAGARDE, Sarah, BLOT, Emmanuel, BOMPAS, Emmanuelle, BOREL, Christian, BOUCHEKOUA, Mohamed, BOZEC LE MOAL, Laurence, BRUYAS, Amandine, CALAIS, Gilles, CARPIUC, Ioana, CHAPET, Sophie, CHATELLIER, Thierry, CHAUFFERT, Bruno, CHELI, Sandrine, CLATOT, Florian, COJOCARASU, Oana, CORNELLY, Alexandre, COUTTE, Alexandre, DALLOZ, Pierre, DARLOY, Franck, DELHOMMEAU, Melissa, DE RAUCOURT, Dominique, DEBELLEIX, Christophe, DEBOURDEAU, Philippe, DILLIES-LEGRAIN, Anne Françoise, DO, Pascal, DUBOS-ARVIS, Catherine, DUCOULOMBIER, Agnès, EL KOURI, Claude, FALKOWSKI, Sabrina, FERRAND, François-Regis, GATINEAU, Michel, GERVAIS, Radj, GRAS, Louis, GUILLET, Pierre, HASBINI, Ali, HENAULT, Stéphane, HERRERA GOMEZ, Ruth Gabriela, HUGUET, Florence, KAMINSKY, Marie Christine, LAGRANGE, Aurélie, LAVAU-DENES, Sandrine, LE CAER, Hervé, LE FOLL, Christine, LEFEBVRE, Gautier, LINOT, Benjamin, LOPEZ, Qian, LORTHOLARY, Alain, MATIAS, Margarida, MAYACHE-BADIS, Lamia, MINNE, Floriane, MOLLON, Delphine, NEIDHARDT, Eve Marie, PAVILLET, Julien, PEYRADE, Frédéric, POINTREAU, Yohann, RAMEE, Jean-François, RAUCHE, Camille, RICHARD, Sandrine, RIZZO, Claudia, ROLLAND, Frédéric, SCHLURMANN, Friderike, STEFANI, Laetitia, TASSY, Louis, TAZI, Youssef, THERY, Jean-Christophe, TORTI EL ZEIN, Florida, TOULLEC, Clémence, TOURANI, Jean-Marc, TOUSSAINT, Philippe, VANBOCKSTAEL, Julie, VAULEON, Elodie, VIRET, Frédéric, WALER, Sabine, ATZPODIEN, Jens, BEHRENS, Caecilia, BUSCH, Chia Jung, DIETZ, Andreas, FELDMANN, Georg, FIETKAU, Rainer, GRANIZKA, Thordis, GREWE, Jürgen, GUNTINAS-LICHINUS, Orlando, HADLER-MIKESCH, Kristina, HAHN, Dennis, INHESTERN, Johanna, KELLNER, Karolin, KLINGHAMMER, Konrad, KRONENBERGER, Roland, LUEDTKE-HECKENKAMP, Kerstin, OCHSENREITHER, Sebastian, OTREMBA, Burkhard, PEUKER, Caroline Anna, PIRLICH, Markus, ROTHMANN, Frank, TOMETTEN, Mareike, WOHLFARTH, Sabine, ZEBRALLA, Veit, ZIPFEL, Matthias, ADANSA KLEIN, Juan Carlos, ARRAZUBI, Virginia, CABALLERO DAROQUI, Javier, CASTELO, Beatriz, CIRAUQUI CIRAUQUI, Beatriz, CRUZ HERNANDEZ, Juan Jesus, GALLEGO, Oscar, IGLESIAS DOCAMPO, Lara Carmen, LOPEZ POUSA, Antonio, MARTINEZ DEL PRADO, Maria, MARTINEZ-TRUFERO, Javier, PASTOR BORGONON, Miguel, PEREZ RUIZ, Elisabeth, QUIROGA GARCIA, Vanesa, RUBIO CASADEVALL, Jordi, VAZQUEZ FERNANDEZ, Silvia, Guigay, Joël, Aupérin, Anne, Fayette, Jérôme, Saada-Bouzid, Esma, Lafond, Cédrik, Taberna, Miren, Geoffrois, Lionnel, Martin, Laurent, Capitain, Olivier, Cupissol, Didier, Castanie, Hélène, Vansteene, Damien, Schafhausen, Philippe, Johnson, Alison, Even, Caroline, Sire, Christian, Duplomb, Sophie, Evrard, Camille, Delord, Jean-Pierre, Laguerre, Brigitte, Zanetta, Sylvie, Chevassus-Clément, Cécile, Fraslin, Aldéric, Louat, Fanny, Sinigaglia, Laura, Keilholz, Ulrich, Bourhis, Jean, and Mesia, Ricard

Published
2021
Full Text
View/download PDF

9. Le Diagnoform Handi: un outil d'évaluation de la condition physique pour les personnes en situation de handicap mêlant recherche et terrain

Author

Barbry, Alexis, Fredonnet, Enguerran, Delrue, Jean, Brand, Arnaud, Coquart, Jeremy, Richard, Sandrine, Pierret, Jonathan, Davinroy, Alexandre, Himbert, Alexine, Ballestra, Constantino, Katuszynski, Ac, Ovigneur, Hervé, Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 (URePSSS), Université d'Artois (UA)-Université du Littoral Côte d'Opale (ULCO)-Université de Lille, Université Paris 13 (UP13), Université de Lorraine (UL), Institut des Rencontres de la Forme [Wattignies] (IRFO), and Comité Régional Olympique et Sportif Hauts-de-France, la Communauté Urbaine d'Arras , Office des Sports d'Arras

Subjects
[SDV]Life Sciences [q-bio]
Abstract

National audience

Published
2022

12. Prognosis of triple-negative breast cancer associated with pregnancy: A propensity score-matched analysis from the French CALG (Cancer Associé à la Grossesse) network

Author

Puchar, Anne, primary, Despierres, Marie, additional, Boudy, Anne-Sophie, additional, Selleret, Lise, additional, Gligorov, Joseph, additional, Richard, Sandrine, additional, Zilberman, Sonia, additional, Ferrier, Clément, additional, Dabi, Yohann, additional, Varlas, Valentin, additional, Thomassin-Naggara, Isabelle, additional, Bendifallah, Sofiane, additional, Touboul, Cyril, additional, and Darai, Emile, additional

Published
2022
Full Text
View/download PDF

13. Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé à La Grossesse) network

Author

Despierres, Marie, primary, Boudy, Anne-Sophie, additional, Selleret, Lise, additional, Gligorov, Joseph, additional, Richard, Sandrine, additional, Thomassin, Isabelle, additional, Dabi, Yohann, additional, Zilberman, Sonia, additional, Touboul, Cyril, additional, Montravers, Françoise, additional, Khaldoun, Kerrou, additional, and Darai, Emile, additional

Published
2021
Full Text
View/download PDF

16. Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associ�� �� La Grossesse) network

Author

Despierres, Marie, Boudy, Anne-Sophie, Selleret, Lise, Gligorov, Joseph, Richard, Sandrine, Thomassin, Isabelle, Dabi, Yohann, Zilberman, Sonia, Touboul, Cyril, Montravers, Fran��oise, Khaldoun, Kerrou, and Darai, Emile

Abstract

The incidence of pregnancy-associated cancers has been increasing for decades. (18F)-FDG Positron Emission Tomography (PET)/Computed Tomography (CT) imaging has become a golden standard in the staging of many malignant diseases. The aims of the current study were to evaluate the feasibility, safety and impact of (18F)-FDG PET/CT performed during pregnancy. A retrospective analysis from the prospective database of the Cancer Associ�� �� La Grossesse (CALG) network (Tenon Hospital, France) including patients who underwent (18F)-FDG PET/CT during their pregnancy between 2015 and 2020. Of the 536 patients for whom advice from the CALG network was requested during the study period, 359 were diagnosed with cancer during pregnancy. Study population was composed of 63 (17.5%) patients who underwent (18F)-FDG PET/CT. Most cancers were diagnosed during the second trimester. Seventy-five percent were diagnosed with breast cancer, mostly locally advanced invasive ductal carcinomas. Median term of pregnancy at PET/CT was 24.8 weeks of gestation. Twelve (19%), 24 (38.1%) and 22 (34.9%) patients underwent the exam during the 1st, 2nd and 3rd trimester, respectively. (18F)-FDG PET/CT resulted in stage modification for 38 (60.3%) of the patients (28 with more extensive lymph node involvement and 10 with metastatic disease) with subsequently/accordingly modified first-line medical treatment. Fifty patients gave birth to healthy newborns. Two patients had a medical termination of pregnancy, five had a medical abortion, one neonatal death occurred in a patient with severe preeclampsia (unrelated to (18F)-FDG PET/CT). The data of 46 children were available at 6 months, 29 at 12 months, and 15 at 24 months. No cases of mental retardation, childhood cancer, or malformation were reported within 2 years. (18F)-FDG PET/CT has a major impact on the management of pregnancy-associated cancers and does not appear to cause fetal side effects suggesting that the exam is feasible during pregnancy as maternal benefits outweigh fetal risks.

Published
2021
Full Text
View/download PDF

17. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

Guigay, Joël, primary, Aupérin, Anne, additional, Fayette, Jérôme, additional, Saada-Bouzid, Esma, additional, Lafond, Cédrik, additional, Taberna, Miren, additional, Geoffrois, Lionnel, additional, Martin, Laurent, additional, Capitain, Olivier, additional, Cupissol, Didier, additional, Castanie, Hélène, additional, Vansteene, Damien, additional, Schafhausen, Philippe, additional, Johnson, Alison, additional, Even, Caroline, additional, Sire, Christian, additional, Duplomb, Sophie, additional, Evrard, Camille, additional, Delord, Jean-Pierre, additional, Laguerre, Brigitte, additional, Zanetta, Sylvie, additional, Chevassus-Clément, Cécile, additional, Fraslin, Aldéric, additional, Louat, Fanny, additional, Sinigaglia, Laura, additional, Keilholz, Ulrich, additional, Bourhis, Jean, additional, Mesia, Ricard, additional, BABA-HAMED, Nabil, additional, BABIN, Emmanuel, additional, BERA, Guillaume, additional, BETRIAN-LAGARDE, Sarah, additional, BLOT, Emmanuel, additional, BOMPAS, Emmanuelle, additional, BOREL, Christian, additional, BOUCHEKOUA, Mohamed, additional, BOZEC LE MOAL, Laurence, additional, BRUYAS, Amandine, additional, CALAIS, Gilles, additional, CARPIUC, Ioana, additional, CHAPET, Sophie, additional, CHATELLIER, Thierry, additional, CHAUFFERT, Bruno, additional, CHELI, Sandrine, additional, CLATOT, Florian, additional, COJOCARASU, Oana, additional, CORNELLY, Alexandre, additional, COUTTE, Alexandre, additional, DALLOZ, Pierre, additional, DARLOY, Franck, additional, DELHOMMEAU, Melissa, additional, DE RAUCOURT, Dominique, additional, DEBELLEIX, Christophe, additional, DEBOURDEAU, Philippe, additional, DILLIES-LEGRAIN, Anne Françoise, additional, DO, Pascal, additional, DUBOS-ARVIS, Catherine, additional, DUCOULOMBIER, Agnès, additional, EL KOURI, Claude, additional, FALKOWSKI, Sabrina, additional, FERRAND, François-Regis, additional, GATINEAU, Michel, additional, GERVAIS, Radj, additional, GRAS, Louis, additional, GUILLET, Pierre, additional, HASBINI, Ali, additional, HENAULT, Stéphane, additional, HERRERA GOMEZ, Ruth Gabriela, additional, HUGUET, Florence, additional, KAMINSKY, Marie Christine, additional, LAGRANGE, Aurélie, additional, LAVAU-DENES, Sandrine, additional, LE CAER, Hervé, additional, LE FOLL, Christine, additional, LEFEBVRE, Gautier, additional, LINOT, Benjamin, additional, LOPEZ, Qian, additional, LORTHOLARY, Alain, additional, MATIAS, Margarida, additional, MAYACHE-BADIS, Lamia, additional, MINNE, Floriane, additional, MOLLON, Delphine, additional, NEIDHARDT, Eve Marie, additional, PAVILLET, Julien, additional, PEYRADE, Frédéric, additional, POINTREAU, Yohann, additional, RAMEE, Jean-François, additional, RAUCHE, Camille, additional, RICHARD, Sandrine, additional, RIZZO, Claudia, additional, ROLLAND, Frédéric, additional, SCHLURMANN, Friderike, additional, STEFANI, Laetitia, additional, TASSY, Louis, additional, TAZI, Youssef, additional, THERY, Jean-Christophe, additional, TORTI EL ZEIN, Florida, additional, TOULLEC, Clémence, additional, TOURANI, Jean-Marc, additional, TOUSSAINT, Philippe, additional, VANBOCKSTAEL, Julie, additional, VAULEON, Elodie, additional, VIRET, Frédéric, additional, WALER, Sabine, additional, ATZPODIEN, Jens, additional, BEHRENS, Caecilia, additional, BUSCH, Chia Jung, additional, DIETZ, Andreas, additional, FELDMANN, Georg, additional, FIETKAU, Rainer, additional, GRANIZKA, Thordis, additional, GREWE, Jürgen, additional, GUNTINAS-LICHINUS, Orlando, additional, HADLER-MIKESCH, Kristina, additional, HAHN, Dennis, additional, INHESTERN, Johanna, additional, KELLNER, Karolin, additional, KLINGHAMMER, Konrad, additional, KRONENBERGER, Roland, additional, LUEDTKE-HECKENKAMP, Kerstin, additional, OCHSENREITHER, Sebastian, additional, OTREMBA, Burkhard, additional, PEUKER, Caroline Anna, additional, PIRLICH, Markus, additional, ROTHMANN, Frank, additional, TOMETTEN, Mareike, additional, WOHLFARTH, Sabine, additional, ZEBRALLA, Veit, additional, ZIPFEL, Matthias, additional, ADANSA KLEIN, Juan Carlos, additional, ARRAZUBI, Virginia, additional, CABALLERO DAROQUI, Javier, additional, CASTELO, Beatriz, additional, CIRAUQUI CIRAUQUI, Beatriz, additional, CRUZ HERNANDEZ, Juan Jesus, additional, GALLEGO, Oscar, additional, IGLESIAS DOCAMPO, Lara Carmen, additional, LOPEZ POUSA, Antonio, additional, MARTINEZ DEL PRADO, Maria, additional, MARTINEZ-TRUFERO, Javier, additional, PASTOR BORGONON, Miguel, additional, PEREZ RUIZ, Elisabeth, additional, QUIROGA GARCIA, Vanesa, additional, RUBIO CASADEVALL, Jordi, additional, and VAZQUEZ FERNANDEZ, Silvia, additional

Published
2021
Full Text
View/download PDF

18. Supplementary Tables and Figure from Behavioural inference from signal processing using animal-borne multi-sensor loggers: a novel solution to extend the knowledge of sea turtle ecology

Author

Jeantet, Lorène, Planas-Bielsa, Víctor, Benhamou, Simon, Geiger, Sebastien, Martin, Jordan, Siegwalt, Flora, Lelong, Pierre, Gresser, Julie, Etienne, Denis, Hiélard, Gaëlle, Arque, Alexandre, Regis, Sidney, Lecerf, Nicolas, Frouin, Cédric, Abdelwahab Benhalilou, Murgale, Céline, Maillet, Thomas, Andreani, Lucas, Campistron, Guilhem, Delvaux, Hélène, Guyon, Christelle, Richard, Sandrine, Lefebvre, Fabien, Aubert, Nathalie, Habold, Caroline, Maho, Yvon Le, and Chevallier, Damien

Subjects
ComputingMethodologies_SIMULATIONANDMODELING, InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL, ComputingMilieux_COMPUTERSANDEDUCATION, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, ComputerApplications_COMPUTERSINOTHERSYSTEMS
Abstract

PDF containing the supplementary tables and figure

Published
2020
Full Text
View/download PDF

19. Feasibility, Safety and Impact of (18F)-FDG PET/CT in patients with pregnancy-associated cancer: experience of the French CALG (Cancer Associé à La Grossesse) network.

Author

Despierres, Marie, Boudy, Anne-Sophie, Selleret, Lise, Gligorov, Joseph, Richard, Sandrine, Thomassin, Isabelle, Dabi, Yohann, Zilberman, Sonia, Touboul, Cyril, Montravers, Françoise, Khaldoun, Kerrou, and Darai, Emile

Subjects
ACQUISITION of data methodology, FIRST trimester of pregnancy, THIRD trimester of pregnancy, RETROSPECTIVE studies, TREATMENT effectiveness, RADIOPHARMACEUTICALS, POSITRON emission tomography, PREGNANCY complications, MEDICAL records, DESCRIPTIVE statistics, DEOXY sugars, COMPUTED tomography, SECOND trimester of pregnancy, PATIENT safety, LONGITUDINAL method, PREGNANCY
Abstract

The incidence of pregnancy-associated cancers has been increasing for decades. (18F)-FDG Positron Emission Tomography (PET)/Computed Tomography (CT) imaging has become a golden standard in the staging of many malignant diseases. The aims of the current study were to evaluate the feasibility, safety and impact of (18F)-FDG PET/CT performed during pregnancy. A retrospective analysis from the prospective database of the Cancer Associé à La Grossesse (CALG) network (Tenon Hospital, France) including patients who underwent (18F)-FDG PET/CT during their pregnancy between 2015 and 2020. Of the 536 patients for whom advice from the CALG network was requested during the study period, 359 were diagnosed with cancer during pregnancy. Study population was composed of 63 (17.5%) patients who underwent (18F)-FDG PET/CT. Most cancers were diagnosed during the second trimester. Seventy-five percent were diagnosed with breast cancer, mostly locally advanced invasive ductal carcinomas. Median term of pregnancy at PET/CT was 24.8 weeks of gestation. Twelve (19%), 24 (38.1%) and 22 (34.9%) patients underwent the exam during the 1st, 2nd and 3rd trimester, respectively. (18F)-FDG PET/CT resulted in stage modification for 38 (60.3%) of the patients (28 with more extensive lymph node involvement and 10 with metastatic disease) with subsequently/accordingly modified first-line medical treatment. Fifty patients gave birth to healthy newborns. Two patients had a medical termination of pregnancy, five had a medical abortion, one neonatal death occurred in a patient with severe preeclampsia (unrelated to (18F)-FDG PET/CT). The data of 46 children were available at 6 months, 29 at 12 months, and 15 at 24 months. No cases of mental retardation, childhood cancer, or malformation were reported within 2 years. (18F)-FDG PET/CT has a major impact on the management of pregnancy-associated cancers and does not appear to cause fetal side effects suggesting that the exam is feasible during pregnancy as maternal benefits outweigh fetal risks. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Behavioural inference from signal processing using animal-borne multi-sensor loggers: a novel solution to extend the knowledge of sea turtle ecology

Author

Jeantet, Lorène, primary, Planas-Bielsa, Víctor, additional, Benhamou, Simon, additional, Geiger, Sebastien, additional, Martin, Jordan, additional, Siegwalt, Flora, additional, Lelong, Pierre, additional, Gresser, Julie, additional, Etienne, Denis, additional, Hiélard, Gaëlle, additional, Arque, Alexandre, additional, Regis, Sidney, additional, Lecerf, Nicolas, additional, Frouin, Cédric, additional, Benhalilou, Abdelwahab, additional, Murgale, Céline, additional, Maillet, Thomas, additional, Andreani, Lucas, additional, Campistron, Guilhem, additional, Delvaux, Hélène, additional, Guyon, Christelle, additional, Richard, Sandrine, additional, Lefebvre, Fabien, additional, Aubert, Nathalie, additional, Habold, Caroline, additional, le Maho, Yvon, additional, and Chevallier, Damien, additional

Published
2020
Full Text
View/download PDF

22. Abstract P2-16-22: Can we improve pCR prediction in early breast cancers treated with neoadjuvant chemotherapy using a simple machine learning algorithm based on 18-FDG and clinico-pathological parameters?

Author

Benderra, Marc-Antoine, primary, Antoine, Martine, additional, Zilberman, Sonia, additional, Richard, Sandrine, additional, Kebir, Fatima, additional, Bendifallah, Sofiane, additional, Lotz, Jean-Pierre, additional, Darai, Emile, additional, Gligorov, Joseph, additional, and Kerrou, Khaldoun, additional

Published
2020
Full Text
View/download PDF

31. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience.

Author

De Giorgi, Ugo, primary, Richard, Sandrine, additional, Badoglio, Manuela, additional, Kanfer, Edward, additional, Bourrhis, Jean Henri, additional, Nicolas-Virelizier, Emmanuelle, additional, Lioure, Bruno, additional, Vettenranta, Kim, additional, Martin, Sonja, additional, Dreger, Peter, additional, Schuler, Markus Kajo, additional, Scarpi, Emanuela, additional, Rosti, Giovanni, additional, Selle, Frédéric, additional, Lanza, Francesco, additional, and Bregni, Marco, additional

Published
2016
Full Text
View/download PDF

33. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study

Author

Selle, Frédéric, primary, Pautier, Patricia, additional, Lhommé, Catherine, additional, Viens, Patrice, additional, Fabbro, Michel, additional, Lokiec, François, additional, Gligorov, Joseph, additional, Richard, Sandrine, additional, Provent, Stéphane, additional, Soares, Daniele G., additional, and Lotz, Jean-Pierre, additional

Published
2015
Full Text
View/download PDF

35. Breast cancer metastasis to the spleen: a case report and literature review.

Author

Fadli, Mohammed EL, Kerrou, Khaldoun, Mhamdi, Hasnae Alaoui, Richard, Sandrine, Khalil, Ahmed, Lotz, Jean-pierre, Belbaraka, Rhizlane, and Gligorov, Joseph

Subjects
BREAST cancer, LITERATURE reviews
Abstract

Splenic metastasis from cancers is extremely rare. They usually occur and are detected simultaneously with metastasis to other organs. We present a case of splenic metastasis from carcinoma of the breast occurring 5 years after initial treatment. The metastatic recurrence was an oligometastic form made from the association of a unique bone metastasis to a rib and the metastasis to the spleen. Treatment of the metastatic recurrence was a second line hormonotherapy as the primitive tumor was estrogen receptors positive and gave a 2 year's long control of the disease. A clinical progression occurred then, the patient complained from pain in the left hypochondrium and was objective on [18F]-FDG PET which leaded to splenectomy. This case is being reported because of the rarity of the lesion and its originality is the first reported case with use of an in vivo demonstration of estrogen receptors expression in the spleen metastasis using PET/CT with 16α-[18F]- Fluoroestradiol. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

38. [What is the cross-disciplinary pathway for a patient receiving gene therapy?]

Author

Richard S and Dorbon C

Subjects
Humans, Child, France, Hospitals
Abstract

The Department of Hematology-Immunology, headed by Professor Jean-Hugues Dalle, is the leading department in France for the care of patients receiving pediatric hematopoietic stem cell transplants. Since 2018, it has been a "major player" in the development of innovative treatments, such as gene therapy. To date, it is the only care service in France, which offers this treatment to stop the neurodegenerative progression of two genetic diseases, in collaboration with the neuropediatric service of the Kremlin-Bicêtre hospital headed by Prof Kumaran Deiva, in conjunction with the national reference center for rare disaeses didicated to leucodystrophies. It is a complex care that requires all the actors a cooperation (parents-children-caregivers)., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)

Published
2024
Full Text
View/download PDF

39. [Lymph node management in endometrial cancer].

Author

Owen C, Bendifallah S, Jayot A, Ilenko A, Arfi A, Boudy AS, Richard S, Varinot J, Thomassin-Naggara I, Bazot M, and Daraï É

Subjects
Female, Humans, Lymph Node Excision, Endometrial Neoplasms secondary, Endometrial Neoplasms therapy, Lymphatic Metastasis pathology, Sentinel Lymph Node Biopsy
Abstract

In 2018, around 382,100 new cases of endometrial cancer (EC) were reported worldwide, accounting for about 4.4% of all new cases of cancer in women. In France, in 2018, the EC is the first gynecological cancer in incidence and the fourth cancer in women. The rationale for the therapeutic management of EC is based on the estimation of a theoretical risk of recurrence and lymph node metastasis using MRI and preoperative biopsy criteria. However, lymph node status remains the determining factor of adjuvant treatment. In order to reduce the morbidity of lymphadenectomy, the concept of sentinel lymph node biopsy (SLN) has been developed. The SLN technique has evolved in recent years, thanks to the advent of robotics and the creation of fluorescence detection cameras. It has been shown that detection of SLN with Indocyanine Green (ICG) allows for more frequent bilateral migration of 88 to 100% and better detection of pelvic GS in 97% of cases with a decrease in morbidity. Recently, in view of the absence of a therapeutic role of lymph node staging, the operational risks and the delay of adjuvant treatments, in case of pelvic lymph node metastasis on definitive histological examination, the question of secondarily performing paraaortic lymphadenectomy arises. The SLN procedure, extended to all early-stage endometrial cancers, should lead to a major reduction in the use of secondary staging and better adaptation of adjuvant therapy., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2020
Full Text
View/download PDF

40. [Metastatic stomach cancer: Clinical trials in Asia and in Occident].

Author

Bui QL, Grazziotin-Soares D, Hasiniatsy RE, Trinh HS, Richard S, Lotz JP, Gligorov J, and Khalil A

Subjects
Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Asian People, Humans, Prognosis, Randomized Controlled Trials as Topic, Stomach Neoplasms ethnology, Trastuzumab therapeutic use, White People, Ramucirumab, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Molecular Targeted Therapy methods, Stomach Neoplasms pathology, Stomach Neoplasms therapy
Abstract

Although cytotoxic chemotherapy is the main therapeutic option to treat gastric cancer in the metastatic setting, molecular targeted agents have recently been introduced in an effort to improve survival outcomes which in average do not exceed 1 year. Trastuzumab and ramucirumab, antibodies directed against HER2 and VEGFR2, respectively, may provide clinical benefit for some patients. Results of clinical studies show that Asian patients have increased survival compared to Caucasian patients. Differences between populations, and in particular the presence of polymorphisms capable of influencing the availability of fluorouracil, have been suggested as possible explanations. Other factors including histology, surgical procedures, administration of neoadjuvant chemotherapy in Western countries and screening programs in Asia have also been suggested. However, none of these elements can fully explain this phenomenon. The aim of this article is to present the main protocols used in clinical practice, the perspectives of metastatic gastric cancer treatment and the particularities observed in Asian and Caucasian patients., (Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2018
Full Text
View/download PDF

41. A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.

Author

Selle F, Pautier P, Lhommé C, Viens P, Fabbro M, Lokiec F, Gligorov J, Richard S, Provent S, Soares DG, and Lotz JP

Subjects
Adenocarcinoma, Clear Cell mortality, Adenocarcinoma, Clear Cell pathology, Adenocarcinoma, Mucinous mortality, Adenocarcinoma, Mucinous pathology, Adolescent, Adult, Aged, Cohort Studies, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cystadenocarcinoma, Serous mortality, Cystadenocarcinoma, Serous pathology, Endometrial Neoplasms mortality, Endometrial Neoplasms pathology, Female, Follow-Up Studies, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Prognosis, Salvage Therapy, Survival Rate, Topotecan administration & dosage, Young Adult, Adenocarcinoma, Clear Cell therapy, Adenocarcinoma, Mucinous therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cystadenocarcinoma, Serous therapy, Endometrial Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Ovarian Neoplasms therapy
Abstract

Background: Dose-intensive chemotherapy with hematopoietic stem cell transplantation has been evaluated as a salvage treatment for recurrent ovarian cancer, but its benefit has not yet been demonstrated. In a previous phase I trial, we reported the feasibility of administering topotecan as a salvage regimen., Methods: Twenty-one patients were treated with escalating doses of topotecan associated with a fixed dose of cyclophosphamide., Results: The maximum tolerated dose was established at 9.0 mg/m2 on a 5-day regimen, analogously to what was reported for topotecan monotherapy. One toxic death from septic shock and multiorgan failure occurred. Although hematopoietic toxicities were overcome by peripheral blood stem cell transplantation, superior nonhematological toxicities were observed as compared to the initial trial., Conclusion: Response rates were generally short and survival rates were poor. Results of the ITOV 01bis study demonstrate that, in the setting of recurrent ovarian cancer, intensive chemotherapy based on topotecan-cyclophosphamide association is not currently clinically indicated., (© 2015 S. Karger AG, Basel.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results